enGene Therapeutics Inc. 8-K

What Happened

• enGene Therapeutics Inc. held its 2026 Annual General Meeting on June 9, 2026 (8:30 a.m. EDT) and reported the final vote results in an 8‑K filed June 10, 2026. A total of 56,196,302 common shares were present or represented by proxy, equal to about 83.89% of the 66,989,466 outstanding shares as of the April 28, 2026 record date.
• Shareholders re-elected the board nominees and approved the appointment and remuneration of the company’s auditor. The 8‑K was signed by CEO Ronald H.W. Cooper.

Key Details

• Meeting attendance: 56,196,302 shares voted (≈83.89% of 66,989,466 outstanding shares as of April 28, 2026).
• Director election vote tallies (For / Withhold / Broker Non‑Votes):
  • Philip Astley‑Sparke: 47,112,414 / 306,821 / 8,777,067
  • Ronald H.W. Cooper: 47,329,848 / 89,387 / 8,777,067
  • Dr. William Grossman: 47,408,163 / 11,072 / 8,777,067
  • Michael Heffernan: 47,408,163 / 11,072 / 8,777,067
• Auditor appointment: 56,180,287 votes For, 16,015 Withhold; no broker non‑votes reported for this item.

Why It Matters

• The vote results confirm continuity of the current board and reappointment of the auditor, which supports governance and operational continuity.
• High participation (≈83.9%) indicates strong shareholder engagement for these routine but important governance items.
• There were no management changes or financial results disclosed in this filing; it is focused on corporate governance votes.